Avidity Biosciences (RNAM) Stock Price, News & Analysis
What Changed
Company Description
Avidity Biosciences (NASDAQ: RNAM) is classified in the biotechnology industry within the Healthcare sector.
For FY2025, Avidity Biosciences reported revenue of $18.8M with net income of -$684.6M and diluted earnings per share of -$4.97.
This page collects what Stock Titan holds for RNAM, including price data, SEC filings, financial highlights, and short interest trends.
Stock Performance
RNAM Metrics & Rankings
Latest News
SEC Filings
Avidity Biosciences has filed 2 recent SEC filings, including 1 Form SCHEDULE 13G/A, 1 Form 15-12G. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all RNAM SEC filings →
Financial Highlights
Avidity Biosciences generated $18.8M in revenue in FY2025, operating income reached -$745.9M, and net income was -$684.6M. Diluted earnings per share stood at -$4.97. The company generated -$650.4M in operating cash flow. The current ratio was 9.20, measuring current assets divided by current liabilities.
Upcoming Events
Short Interest History
Days to Cover History
RNAM Company Profile & Sector Positioning
Avidity Biosciences (RNAM) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing RNAM often look at related companies in the same sector, including Vertex Pharmaceuticals Inc (VRTX), Regeneron Pharmaceuticals Inc (REGN), Moderna, Inc. (MRNA), argenx SE (ARGX), and Revolution Medicines, Inc. (RVMD). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate RNAM's relative position within its industry.